This study is one of the few prospective, randomized, placebo-controlled studies to investigate the effects of human recombinant thrombomodulin, ART-123, in the treatment of DIC associated with infectious systemic inflammatory response syndrome (SIRS). Here, THBD is linked to systemic inflammatory response syndrome.